HLA-C*06:02 Status and Differential Response to Ustekinumab in Patients With Psoriasis | Dermatology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With PsoriasisA Systematic Review and Meta-analysis

Educational Objective
To evaluate whether HLA-C*060:02 status is associated with a differential response to ustekinumab in patients with psoriasis.
1 Credit CME
Key Points

Question  Is HLA-C*06:02 status associated with a differential response to ustekinumab therapy in patients with psoriasis?

Findings  This systematic review and meta-analysis of 8 studies and 1048 patients showed a risk difference for achievement of 75% improvement in Psoriasis Area and Severity Index (PASI75) after 6 months of ustekinumab therapy in favor of HLA-C*06:02–positive patients. Although HLA-C*06:02–positive patients had a high PASI75 response rate after 6 months, the PASI75 response rate was also high in the HLA-C*06:02–negative group.

Meaning  Based on high PASI75 response rates in both genotype groups, there appears to be no rationale for excluding patients from ustekinumab treatment based on a negative HLA-C*06:02 status.

Abstract

Importance  Previous research showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis but consisted mostly of small (and sometimes inconclusive) cohort studies.

Objective  To assess whether HLA-C*06:02 status is associated with a differential response to ustekinumab therapy in patients with psoriasis through a systematic review and a meta-analysis of available data.

Data Sources  A comprehensive search was conducted using MEDLINE, Embase, the Cochrane Library, Web of Science, and gray literature sources. Databases were searched from January 1, 2000, to May 14, 2018. Search strategies included terms and synonyms for psoriasis, HLA-C, and ustekinumab. Languages were restricted to English, French, German, and Dutch.

Study Selection  Studies were included if they reported the association between HLA-C*06:02 status and 75% improvement in Psoriasis Area and Severity Index (PASI75) response to ustekinumab therapy in patients with plaque psoriasis after 6 and/or 3 months of treatment. Randomized clinical trials and observational studies were included. Screening and selection were performed independently by 2 reviewers.

Data Extraction and Synthesis  HLA-C*06:02 genotype status and PASI75 response rates were extracted by 2 reviewers. Data were pooled using random-effects models. Heterogeneity was assessed using the τ2 and I2 statistic. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines were followed.

Main Outcome and Measure  The primary outcome was the risk difference of achieving PASI75 after 6 months of ustekinumab therapy between HLA-C*06:02–positive and HLA-C*06:02–negative patients.

Results  A total of 8 studies were reviewed; 1048 patients were included for meta-analyses, and 937 patients were included for the primary analysis of PASI75 response after 6 months of treatment. Random-effects meta-analysis showed a risk difference of 0.24 (95% CI, 0.14-0.35; P < .001) in favor of HLA-C*06:02–positive patients. The median PASI75 response rate in the HLA-C*06:02–positive group was 92% (pooled, 89%; range, 62%-98%). For HLA-C*06:02–negative patients, the median response rate was 67% (pooled, 62%; range, 40%-84%). Substantial heterogeneity may have been present, with an I2 of 82%.

Conclusions and Relevance  The meta-analysis showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis. Although HLA-C*06:02–positive patients had high PASI75 response rates after 6 months, the PASI75 response rate was also high in the HLA-C*06:02–negative group. There appears to be no rationale for excluding patients from ustekinumab treatment based on a negative HLA-C*06:02 status.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: January 15, 2019.

Corresponding Author: Lieke J. van Vugt, MD, Department of Dermatology, Radboud University Medical Centre, Radboud Institute of Health Sciences, PO Box 9101, 6500 HB Nijmegen, the Netherlands (lieke.vanvugt@radboudumc.nl).

Published Online: April 17, 2019. doi:10.1001/jamadermatol.2019.0098

Author Contributions: Dr van Vugt had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: van Vugt, van den Reek, Hannink.

Administrative, technical, or material support: Coenen, de Jong.

Supervision: van den Reek, Hannink, Coenen, de Jong.

Conflict of Interest Disclosures: All funding received by the authors goes to the independent research fund of the Department of Dermatology of Radboud University Medical Center, Nijmegen, the Netherlands. Dr van Vugt reported carrying out clinical trials for AbbVie, Celgene, Janssen, and Novartis. Dr van den Reek reported carrying out clinical trials for AbbVie and Janssen, receiving speaking fees from AbbVie and Eli Lilly and Company, and receiving reimbursement for attending a symposium from Janssen, Pfizer, and AbbVie. Dr de Jong reported receiving research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center, Nijmegen, the Netherlands, from AbbVie, Pfizer, and Janssen Pharmaceutica and acting as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Janssen Pharmaceutica, Novartis, Eli Lily and Company, Celgene, and Leo Pharma. No other disclosures were reported.

References
1.
Parisi  R, Symmons  DP, Griffiths  CE, Ashcroft  DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence.  J Invest Dermatol. 2013;133(2):377-385. doi:10.1038/jid.2012.339PubMedGoogle ScholarCrossref
2.
Lowes  MA, Suárez-Fariñas  M, Krueger  JG.  Immunology of psoriasis.  Annu Rev Immunol. 2014;32:227-255. doi:10.1146/annurev-immunol-032713-120225PubMedGoogle ScholarCrossref
3.
Schmitt  J, Rosumeck  S, Thomaschewski  G, Sporbeck  B, Haufe  E, Nast  A.  Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.  Br J Dermatol. 2014;170(2):274-303. doi:10.1111/bjd.12663PubMedGoogle ScholarCrossref
4.
Zweegers  J, Otero  ME, van den Reek  JM,  et al.  Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: a systematic review.  Acta Derm Venereol. 2016;96(4):453-458. doi:10.2340/00015555-2276PubMedGoogle ScholarCrossref
5.
Hu  Y, Chen  Z, Gong  Y, Shi  Y.  A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis.  Clin Drug Investig. 2018;38(3):191-199. doi:10.1007/s40261-017-0603-3PubMedGoogle Scholar
6.
van Vugt  LJ, van den Reek  JMPA, Coenen  MJH, de Jong  EMGJ.  A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis.  Br J Dermatol. 2018;178 (1):86-94. doi:10.1111/bjd.15753PubMedGoogle Scholar
7.
Talamonti  M, Botti  E, Galluzzo  M,  et al.  Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.  Br J Dermatol. 2013;169(2):458-463. doi:10.1111/bjd.12331PubMedGoogle ScholarCrossref
8.
Talamonti  M, Galluzzo  M, Chimenti  S, Costanzo  A.  HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up.  J Am Acad Dermatol. 2016;74(2):374-375. doi:10.1016/j.jaad.2015.08.055PubMedGoogle ScholarCrossref
9.
Chiu  HY, Huang  PY, Jee  SH,  et al.  HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis.  Br J Dermatol. 2012;166(2):288-297. doi:10.1111/j.1365-2133.2011.10688.xPubMedGoogle ScholarCrossref
10.
Chiu  HY, Wang  TS, Chan  CC, Cheng  YP, Lin  SJ, Tsai  TF.  Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.  Br J Dermatol. 2014;171(5):1181-1188. doi:10.1111/bjd.13056PubMedGoogle ScholarCrossref
11.
Galluzzo  M, Boca  AN, Botti  E,  et al.  IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis.  Dermatology. 2016;232(2):230-236. doi:10.1159/000441719PubMedGoogle ScholarCrossref
12.
Stroup  DF, Berlin  JA, Morton  SC,  et al.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.  JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008PubMedGoogle ScholarCrossref
13.
Moher  D, Liberati  A, Tetzlaff  J, Altman  DG; PRISMA Group.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement.  BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535PubMedGoogle ScholarCrossref
14.
IntHout  J, Ioannidis  JP, Rovers  MM, Goeman  JJ.  Plea for routinely presenting prediction intervals in meta-analysis.  BMJ Open. 2016;6(7):e010247. doi:10.1136/bmjopen-2015-010247PubMedGoogle ScholarCrossref
15.
Wells  GA, Shea  B, O’Connell  D,  et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed February 19, 2018.
16.
Talamonti  M, Galluzzo  M, van den Reek  JM,  et al.  Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.  Br J Dermatol. 2017;177(2):489-496. doi:10.1111/bjd.15387PubMedGoogle ScholarCrossref
17.
van den Reek  JMPA, Coenen  MJH, van de L'Isle Arias M, et al.  Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.  Br J Dermatol. 2017;176(5):1288-1296. doi:10.1111/bjd.15005PubMedGoogle Scholar
18.
Li  K, Huang  CC, Randazzo  B,  et al.  HLA-C*06:02 allele and response to IL-12/23 inhibition: results from the ustekinumab phase 3 psoriasis program.  J Invest Dermatol. 2016;136(12):2364-2371. doi:10.1016/j.jid.2016.06.631PubMedGoogle ScholarCrossref
19.
Raposo  I, Carvalho  C, Bettencourt  A,  et al.  Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.  Eur J Dermatol. 2017;27(5):528-530.PubMedGoogle Scholar
20.
Anzengruber  F, Ghosh  A, Maul  JT, Drach  M, Navarini  AA.  Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis.  Psoriasis (Auckl). 2018;8:7-11.PubMedGoogle Scholar
21.
Dand  N.  Genetic variation contributes to response to biologics: initial findings of the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium.  Br J Dermatol. 2017;177(5):e237.Google Scholar
22.
Dand  N; PSORT Consortium.  Psoriasis Stratification to Optimise Relevant Therapy (PSORT): genome-wide study reveals genetic drivers of response to biologic therapy in psoriasis.  J Invest Dermatol. 2017;137(10)(suppl 2):S225. doi:10.1016/j.jid.2017.07.185Google ScholarCrossref
23.
Puig  L.  PASI90 response: the new standard in therapeutic efficacy for psoriasis.  J Eur Acad Dermatol Venereol. 2015;29(4):645-648. doi:10.1111/jdv.12817PubMedGoogle ScholarCrossref
24.
Abrouk  M, Nakamura  M, Zhu  TH, Farahnik  B, Koo  J, Bhutani  T.  The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.  J Dermatolog Treat. 2017;28(6):488-491. doi:10.1080/09546634.2016.1278198PubMedGoogle ScholarCrossref
25.
Higgins  JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http://www.handbook-5-1.cochrane.org. Accessed on December 12, 2016.
26.
Capon  F.  The genetic basis of psoriasis.  Int J Mol Sci. 2017;18(12):E2526. doi:10.3390/ijms18122526PubMedGoogle ScholarCrossref
27.
Bowcock  AM.  The genetics of psoriasis and autoimmunity.  Annu Rev Genomics Hum Genet. 2005;6:93-122. doi:10.1146/annurev.genom.6.080604.162324PubMedGoogle ScholarCrossref
28.
Chen  L, Tsai  TF.  HLA-Cw6 and psoriasis.  Br J Dermatol. 2018;178 (4):854-862. doi:10.1111/bjd.16083PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close